Science

Added receptor helps CAR T cells stay in bone marrow in cancer mouse models

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 13:10:24 UTC.

Briefings

A recent study reports that adding a specific receptor to CAR T cells allows them to remain in the bone marrow of cancer mouse models, potentially extending the treatment's reach to solid tumors. This finding addresses a major limitation of current CAR T-cell therapies, which typically fail when cancer cells escape the bloodstream and enter tissues like the bone marrow.

Key points

• Adding a specific receptor enables CAR T cells to persist in the bone marrow of cancer mouse models.
• This mechanism may allow CAR T-cell therapy to be extended to solid tumors, including those that have spread to the bone.

Context

CAR T-cell therapy has revolutionized blood cancer treatment but struggles with solid tumors due to limited ability to stay in tissues like the bone. This breakthrough addresses that specific barrier.

Limitations

Evidence is limited to mouse models; human clinical application remains untested. The specific receptor and its mechanism are identified but not fully characterized in this snapshot.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 13:43:48 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieucgalg7nkv2ufgzclvrfbiwngydputgdnfe6vup7os3avdvt57a